Dietger Niederwieser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4663486/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, 2022, 36, 90-99.	7.2	42
2	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 2022, 107, 1045-1053.	3.5	87
3	Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15. Bone Marrow Transplantation, 2022, , .	2.4	0
4	Current Status of CPX-351 Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 575-580.	0.4	4
5	Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012. Bone Marrow Transplantation, 2022, 57, 881-888.	2.4	7
6	Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bone Marrow Transplantation, 2022, 57, 423-430.	2.4	27
7	A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar. Immunotherapy, 2022, , .	2.0	1
8	Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 614-621.	2.4	4
9	ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 936-945.	2.4	19
10	Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. Transplantation and Cellular Therapy, 2021, 27, 270.e1-270.e6.	1.2	17
11	The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge. Bone Marrow Transplantation, 2021, 56, 1229-1231.	2.4	4
12	Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell Transplantation. HemaSphere, 2021, 5, e532.	2.7	9
13	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplantation and Cellular Therapy, 2021, 27, 267.e1-267.e5.	1.2	6
14	Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. Leukemia, 2021, 35, 2539-2551.	7.2	51
15	Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. Blood Cancer Journal, 2021, 11, 80.	6.2	13
16	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1426-1436.	1.6	49
17	Clinical value of the measurable residual disease status within the <scp>ELN2017</scp> risk groups in <scp>AML</scp> patients undergoing allogeneic stem cell transplantation. American Journal of Hematology, 2021, 96, E237-E239.	4.1	3
18	Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response. Nature Cancer, 2021, 2, 527-544.	13.2	37

#	Article	IF	CITATIONS
19	Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Annals of Hematology, 2021, 100, 2387-2398.	1.8	11
20	Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2610-2612.	2.4	4
21	Clinical implications of <scp><i>SRSF2</i></scp> mutations in <scp>AML</scp> patients undergoing allogeneic stem cell transplantation. American Journal of Hematology, 2021, 96, 1287-1294.	4.1	10
22	Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. Journal of Clinical Oncology, 2021, 39, 2881-2892.	1.6	59
23	Strategic priorities for hematopoietic stem cell transplantation in the EMRO region. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	3
24	Increasing access to allogeneic hematopoietic cell transplant: an international perspective. Hematology American Society of Hematology Education Program, 2021, 2021, 264-274.	2.5	14
25	Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome. Frontiers in Oncology, 2021, 11, 749691.	2.8	Ο
26	Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Leukemia and Lymphoma, 2020, 61, 377-386.	1.3	14
27	Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2020, 55, 729-739.	2.4	4
28	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Bone Marrow Transplantation, 2020, 55, 172-181.	2.4	10
29	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 7-16	0.9	17
30	Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic cell transplantation program (Part I): Minimum requirements and beyond. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 131-142.	0.9	14
31	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplantation, 2020, 55, 698-707.	2.4	4
32	Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematology,the, 2020, 7, e28.e39	4.6	94
33	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLAâ€matched allogeneic stem cell transplantation. American Journal of Hematology, 2020, 95, 282-294.	4.1	7
34	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia, 2020, 34, 1090-1101.	7.2	34
35	Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product. Targeted Oncology, 2020, 15, 599-611.	3.6	12
36	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	5.2	34

Dietger Niederwieser

#	Article	IF	CITATIONS
37	No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group. Leukemia and Lymphoma, 2020, 61, 2821-2830.	1.3	0
38	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biology of Blood and Marrow Transplantation, 2020, 26, 2181-2189.	2.0	51
39	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. Biology of Blood and Marrow Transplantation, 2020, 26, 2372-2377.	2.0	19
40	Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML. Annals of Hematology, 2020, 99, 2417-2427.	1.8	1
41	Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Advances, 2020, 4, 3864-3874.	5.2	36
42	High expression of the stem cell marker <i>GPR56</i> at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population. Haematologica, 2020, 105, e507.	3.5	12
43	A post-stem cell transplant risk score for Philadelphia-negative acute lymphoblastic leukemia. Haematologica, 2020, 105, 1177-1179.	3.5	1
44	European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 2020, 34, 966-984.	7.2	875
45	Outcomes of Older Patients with <i>NPM1</i> Mutated and <i>FLT3</i> â€ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation. HemaSphere, 2020, 4, e326.	2.7	6
46	Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. New England Journal of Medicine, 2020, 382, 1800-1810.	27.0	455
47	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	1.4	127
48	Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplantation, 2019, 54, 402-417.	2.4	31
49	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone Marrow Transplantation, 2019, 54, 44-52.	2.4	59
50	Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia. EClinicalMedicine, 2019, 15, 33-41.	7.1	8
51	Comparison of nonâ€myeloablative and reducedâ€intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. American Journal of Hematology, 2019, 94, 1344-1352.	4.1	7
52	Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. British Journal of Cancer, 2019, 121, 751-757.	6.4	17
53	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1975-1983	2.0	61
54	Use of busulfan in conditioning for allogeneic hematopoietic stem cell transplantation in adults: a survey by the Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 2013-2019.	2.4	21

#	Article	IF	CITATIONS
55	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. Biology of Blood and Marrow Transplantation, 2019, 25, 2322-2329.	2.0	21
56	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. Biology of Blood and Marrow Transplantation, 2019, 25, 2330-2337.	2.0	22
57	Pretreatment CD34+/CD38– Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1560-1566.	2.0	5
58	Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica, 2019, 104, 1782-1788.	3.5	48
59	Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement. Bone Marrow Transplantation, 2019, 54, 1738-1746.	2.4	13
60	"Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries― Bone Marrow Transplantation, 2019, 54, 1179-1188.	2.4	51
61	Prognostic Impact of Blood <i>MN1</i> Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia. HemaSphere, 2019, 3, e167.	2.7	20
62	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. Biology of Blood and Marrow Transplantation, 2019, 25, 86-93.	2.0	21
63	Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. Leukemia, 2019, 33, 686-695.	7.2	24
64	Phospholipase A2 products predict the hematopoietic support capacity of horse serum. Differentiation, 2019, 105, 27-32.	1.9	5
65	EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica, 2019, 104, 947-954.	3.5	33
66	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 81-87.	3.8	42
67	Optimized Digital Droplet PCR for BCR-ABL. Journal of Molecular Diagnostics, 2019, 21, 27-37.	2.8	26
68	Clinical and morphological practices in the diagnosis of transplant-associated microangiopathy: a study on behalf of Transplant Complications Working Party of the EBMT. Bone Marrow Transplantation, 2019, 54, 1022-1028.	2.4	19
69	Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an <scp>ALWP</scp> / <scp>EBMT</scp> analysis. Journal of Internal Medicine, 2019, 285, 407-418.	6.0	35
70	The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood, 2019, 133, 550-565.	1.4	57
71	Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation, 2019, 54, 1189-1197.	2.4	34
72	One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Blood, 2019, 134, 2035-2035.	1.4	36

Dietger Niederwieser

#	Article	IF	CITATIONS
73	Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response. Blood, 2019, 134, 495-495.	1.4	13
74	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplantation, 2018, 53, 683-691.	2.4	13
75	Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 640-643.	2.4	0
76	Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60Âyears and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. Journal of Hematology and Oncology, 2018, 11, 55.	17.0	51
77	Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory WaldenstrA¶m macroglobulinemia: evidence for a graft- <i>versus</i> -lymphoma effect. Haematologica, 2018, 103, e252-e255.	3.5	2
78	Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1188-1192.	2.4	7
79	Transplant results in adults with Fanconi anaemia. British Journal of Haematology, 2018, 180, 100-109.	2.5	25
80	Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Annals of Hematology, 2018, 97, 1757-1765.	1.8	57
81	MicroRNA-143 targets ERK5 in granulopoiesis and predicts outcome of patients with acute myeloid leukemia. Cell Death and Disease, 2018, 9, 814.	6.3	23
82	Internet-based grief therapy for bereaved individuals after loss due to Haematological cancer: study protocol of a randomized controlled trial. BMC Psychiatry, 2018, 18, 52.	2.6	16
83	Competing-risk outcomes after hematopoietic stem cell transplantation from the perspective of time-dependent effects. Haematologica, 2018, 103, 1527-1534.	3.5	5
84	Phase II Study of Stimulation of Healthy Sibling Donors with Single-Shot Pegfilgrastim - Update (EUDRACT Nr: 2005-004971-39). Blood, 2018, 132, 2064-2064.	1.4	0
85	Latin America: the next region for haematopoietic transplant progress. Bone Marrow Transplantation, 2017, 52, 671-677.	2.4	39
86	Prognostic impact of the CD34+/CD38â^' cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. American Journal of Hematology, 2017, 92, 388-396.	4.1	25
87	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 2017, 129, 1753-1762.	1.4	278
88	Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning. Bone Marrow Transplantation, 2017, 52, 932-935.	2.4	13
89	Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV). Journal of Cancer Research and Clinical Oncology, 2017, 143, 2049-2058.	2.5	7
90	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation. New England Journal of Medicine, 2017, 377, 454-464.	27.0	1,628

#	Article	IF	CITATIONS
91	Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality. Biology of Blood and Marrow Transplantation, 2017, 23, 1582-1587.	2.0	3
92	Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosomeâ€positive leukemias with the T315I mutation. Cancer, 2017, 123, 2875-2880.	4.1	79
93	Alloreactivity: the Janus-face of hematopoietic stem cell transplantation. Leukemia, 2017, 31, 1752-1759.	7.2	23
94	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017, 129, 424-447.	1.4	4,375
95	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2017, 52, 372-380.	2.4	53
96	Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077). Journal of Cancer Research and Clinical Oncology, 2017, 143, 2545-2553.	2.5	10
97	Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation. Haematologica, 2017, 102, 796-803.	3.5	4
98	Features of lineage-specific hematopoietic metabolism revealed by mitochondrial proteomics. Proteomics, 2017, 17, 1700053.	2.2	1
99	Disruption of the C/EBPα—miR-182 balance impairs granulocytic differentiation. Nature Communications, 2017, 8, 46.	12.8	38
100	Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biology of Blood and Marrow Transplantation, 2017, 23, 44-52.	2.0	49
101	The EBMT–ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. Bone Marrow Transplantation, 2017, 52, 357-362.	2.4	13
102	Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors—A Retrospective Study. PLoS ONE, 2017, 12, e0169512.	2.5	28
103	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia―antigens. Oncotarget, 2017, 8, 43915-43924.	1.8	12
104	High <i>BAALC</i> copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. Oncotarget, 2017, 8, 87944-87954.	1.8	19
105	Unsupervised hierarchical clustering of surface antigen expression to identify normal karyotype AML patients with distinct disease characteristics and poor outcome Journal of Clinical Oncology, 2017, 35, 7042-7042.	1.6	Ο
106	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica, 2016, 101, 256-262.	3.5	42
107	Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation. Blood, 2016, 128, 3169-3176.	1.4	41
108	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. Haematologica, 2016, 101, 773-780.	3.5	35

#	Article	IF	CITATIONS
109	The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50Âyears—a report from the EBMT acute leukemia working party. Journal of Hematology and Oncology, 2016, 9, 65.	17.0	17
110	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. Biology of Blood and Marrow Transplantation, 2016, 22, 1874-1882.	2.0	78
111	Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. JAMA - Journal of the American Medical Association, 2016, 315, 198.	7.4	18
112	Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation, 2016, 22, 23-26.	2.0	70
113	Reprint of: Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biology of Blood and Marrow Transplantation, 2016, 22, S15-S18.	2.0	47
114	Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplantation, 2016, 51, 778-785.	2.4	259
115	Long-term follow-up of the AML97 study for patients aged 60Âyears and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). Journal of Cancer Research and Clinical Oncology, 2016, 142, 305-315.	2.5	19
116	Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study. Blood, 2016, 128, 1066-1066.	1.4	5
117	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase, Blood, 2016, 128, 3094-3094.	1.4	11
118	Comparison of Allogeneic Stem Cell Transplantation for Transformed Acute Myeloid Leukemia Derived from MDS, CMML or MPN. a Report of the Chronic Malignancies Working Party of EBMT. Blood, 2016, 128, 3499-3499.	1.4	2
119	Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). Blood. 2016, 128, 4599-4599.	1.4	3
120	Ibrutinib for Bridging to Allogeneic Hematopoietic Stem Cell Transplantation (alloHCT) in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Is Safe and Effective: First Results of a Survey By the Chronic Malignancy and the Lymphoma Working Parties of the EBMT. Blood, 2016, 128, 4657-4657.	1.4	7
121	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. Blood, 2016, 128, 589-589.	1.4	11
122	High Blood BAALC Copy Numbers Determined By Digital Droplet PCR at Timepoint of Allogeneic Transplantation in Complete Remission Predicts Relapse in Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 517-517.	1.4	0
123	HLA Ligandome Analysis of Different Hematological Malignancies Identifies a Small Panel of "Pan-Leukemia"-Associated Antigens. Blood, 2016, 128, 2169-2169.	1.4	0
124	Allogeneic Hematopoietic Cell Transplantation in Elderly Patients Aged 65 and Older: A Retrospective Analysis By the Complications and Quality of Life Working Party of the EBMT. Blood, 2016, 128, 681-681.	1.4	4
125	Mapping the HLA Ligandome Landscape of Chronic Myeloid Leukemia Identifies Novel CD8+ and CD4+ T Cell-Epitopes for Immunotherapeutic Approaches. Blood, 2016, 128, 4232-4232.	1.4	1
126	Absolute Quantification of Pre-microRNA-155 Copy Numbers By Digital Droplet PCR Identifies Acute Myeloid Leukemia (AML) Patients with Adverse Outcome. Blood, 2016, 128, 1698-1698.	1.4	0

#	Article	IF	CITATIONS
127	Biological Associations and Clinical Impact of Differential Expression of the Pre-Mir-29a/b-1 and Pre-Mir-29b-2/C Clusters in Acute Myeloid Leukemia. Blood, 2016, 128, 5110-5110.	1.4	0
128	High Expression of ZBTB7A at Diagnosis Associated with Inferior Outcome in Acute Myeloid Leukemia Patients Receiving Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5092-5092.	1.4	0
129	HCT Outcome in Patients with Fanconi Anemia Transplanted at Adult Age. Blood, 2016, 128, 4691-4691.	1.4	0
130	Economics and Outcome After Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. EBioMedicine, 2015, 2, 2101-2109.	6.1	36
131	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. British Journal of Haematology 2015, 171, 239-246	2.5	80
132	PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Research, 2015, 75, 3411-3424.	0.9	39
133	Comparison of Unrelated Cord Blood and Peripheral Blood Stem Cell Transplantation in Adults with Myelodysplastic Syndrome after Reduced-Intensity Conditioning Regimen: A Collaborative Study from Eurocord (Cord blood Committee of Cellular Therapy & Immunobiology Working Party of EBMT) and Chronic Malignancies Working Party. Biology of Blood and Marrow Transplantation, 2015, 21,	2.0	53
134	409-195. One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematology,the, 2015, 2, e91-e100.	4.6	329
135	Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2193-2203.	2.5	5
136	Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2013-2022.	2.5	11
137	Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML—long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Annals of Oncology, 2015, 26, 1430	1.2	9
	A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding) Tj ETQq0 0 0) rgBT /Ov	erlock 10 Tf 5
138	and Oncology (OSHO), 2010–2012. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1639-1644.	2.5	6
139	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia, 2015, 29, 2126-2133.	7.2	242
140	Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplantation, 2015, 50, 1542-1550.	2.4	80
141	Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biology of Blood and Marrow Transplantation, 2015, 21, 2052-2060.	2.0	48
142	NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia, 2015, 29, 535-547.	7.2	120
143	The EBMT Score Predicts Transplant Related Mortality and Overall Survival after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. Blood, 2015, 126, 3223-3223.	1.4	2
144	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase. Blood, 2015, 126, 4040-4040.	1.4	7

#	Article	IF	CITATIONS
145	The Impact of Ponatinib Versus Allogeneic Stem Cell Transplant (SCT) on Outcomes in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) with the T315I Mutation. Blood, 2015, 126, 480-480.	1.4	5
146	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]), Blood, 2015, 126, 6-6.	1.4	104
147	Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 63-63.	1.4	1
148	Assessment of NPM1 Type a Mutation Burden By Digital Droplet PCR As a Marker of Minimal Residual Disease in Acute Myeloid Leukemia Patients Undergoing Stem Cell Transplantation. Blood, 2015, 126, 4398-4398.	1.4	0
149	Outcome of Patients with Myelofibrosis Relapsing after Allogeneic Stem Cell Transplant: A Retrospective Study By the Chronic Malignancies Working Party of EBMT. Blood, 2015, 126, 1958-1958.	1.4	Ο
150	Inclusion of Plerixafor Increases the Efficacy of Stem Cell Harvesting in Poorly Mobilizing Patients with Multiple Myeloma and Lymphoma. Blood, 2015, 126, 5439-5439.	1.4	0
151	Prognostic Impact of Aberrant RUNX1 Expression in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 3829-3829.	1.4	Ο
152	Unsupervised Cluster Analysis of Antigen Expression Patterns Identifies Subgroups with Distinct Biological and Clinical Features in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 2573-2573.	1.4	0
153	Allogeneic Stem Cell Transplantation for MDS Patients More Than 70 Years of Age: a Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party (CMWP) of the EBMT. Blood, 2015, 126, 4390-4390.	1.4	1
154	High Expression of the Hedgehog Transcription Factor GLI1 Is Associated with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Non-Myeloablative Conditioning. Blood, 2015, 126, 2032-2032.	1.4	0
155	Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies. Blood, 2015, 126, 2517-2517.	1.4	0
156	Value of liver elastography and abdominal ultrasound for detection of complications of allogeneic hemopoietic SCT. Bone Marrow Transplantation, 2014, 49, 806-811.	2.4	16
157	Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. Leukemia and Lymphoma, 2014, 55, 1274-1280.	1.3	4
158	The role of hypomethylating agents in the treatment of elderly patients with AML. Journal of Geriatric Oncology, 2014, 5, 89-105.	1.0	49
159	Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice. Bone Marrow Transplantation, 2014, 49, 168-173.	2.4	252
160	Essential requirements for setting up a stem cell processing laboratory. Bone Marrow Transplantation, 2014, 49, 1098-1105.	2.4	35
161	Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1947-1956.	2.5	30
162	Elucidating functional heterogeneity in hematopoietic progenitor cells: A combined experimental and modeling approach. Experimental Hematology, 2014, 42, 826-837.e17.	0.4	6

#	Article	IF	CITATIONS
163	Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica, 2014, 99, 1204-1211.	3.5	42
164	Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood, 2014, 123, 1353-1360.	1.4	231
165	High Pri-Mir-181a-1 and Pri-Mir-181a-2 Expression Associates with Improved Outcomes in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning. Blood, 2014, 124, 732-732.	1.4	0
166	Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. Journal of Cancer Research and Clinical Oncology, 2013, 139, 499-508.	2.5	33
167	Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1937-1946.	2.5	35
168	Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplantation, 2013, 48, 220-225.	2.4	46
169	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica, 2013, 98, 1282-1290.	3.5	110
170	Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial <scp>OSHO</scp> – #077. British Journal of Haematology, 2013, 162, 202-209.	2.5	28
171	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 1530-1538.	1.6	197
172	Prognostic Significance Of EVI1 expression In Acute Myeloid Leukemia Patients With Intermediate and Adverse Cytogenetic Risk Undergoing Allogeneic Hematopoietic Cell Transplantation With Reduced-Intensity Conditioning. Blood, 2013, 122, 3383-3383.	1.4	1
173	Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data. PLoS ONE, 2013, 8, e74368.	2.5	25
174	Outcome Of MDS and AML With MDS-Related Changes: Treatment Versus Prognostic Factors. Blood, 2013, 122, 5223-5223.	1.4	0
175	Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program. Bone Marrow Transplantation, 2012, 47, 15-17.	2.4	21
176	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature Reviews Clinical Oncology, 2012, 9, 579-590.	27.6	352
177	Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood, 2012, 119, 1599-1606.	1.4	254
178	Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leukemia and Lymphoma, 2012, 53, 110-117.	1.3	98
179	Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. Journal of Cancer Research and Clinical Oncology, 2012, 138, 1405-1412.	2.5	41
180	Mobilized peripheral blood stem cells compared with bone marrow from <scp>HLA</scp> â€identical siblings for reducedâ€intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the <scp>A</scp> cute Leukemia <scp>W</scp> orking <scp>P</scp> arty of <scp>EBMT</scp> . European Journal of Haematology, 2012, 89, 206-213.	2.2	20

#	Article	IF	CITATIONS
181	Docetaxel (T), cisplatin (P), and TP 5-fluorouracil (F) with or without cetuximab in head and neck squamous cell carcinoma (HNSCC): Simulation of ex vivo results in the FLAVINO-assay Journal of Clinical Oncology, 2012, 30, e16016-e16016.	1.6	0
182	Inactivation of the Cell Fate Determinate Llgl1 (Lethal Giant Larvae Homolog 1) Leads to Enhanced HSC Fitness and Predicts a Poor Prognosis in AML Blood, 2012, 120, 2293-2293.	1.4	0
183	Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP) Blood, 2012, 120, 3041-3041.	1.4	0
184	Trends of Hematopoietic Stem Cell Transplantation in the Eastern Mediterranean Region, 1984-2007. Biology of Blood and Marrow Transplantation, 2011, 17, 1352-1361.	2.0	20
185	Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia, 2011, 25, 498-505.	7.2	70
186	Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. JAMA - Journal of the American Medical Association, 2011, 306, 1874.	7.4	274
187	Delayed Processing of Bone Marrow Samples Reveals a Prognostic Pattern of NME mRNA Expression in Cytogenetically Normal AML. Blood, 2011, 118, 4904-4904.	1.4	0
188	C/EBPα-Induced MicroRNA 30c Inactivates Notch1 During Granulopoiesis and Is Downregulated In Acute Myeloid Leukemia. Blood, 2011, 118, 2368-2368.	1.4	0
189	Kinetics of Engraftment and Predictors of Outcome in Patients with Advanced Chronic Lymphocytic Leukaemia (CLL) After Treatment with Low Dose Total Body Irradiation (TBI) Followed by related or unrelated hematopoietic Stem Cell Transplantation. Blood, 2011, 118, 4532-4532.	1.4	0
190	Comparable Outcome After Single-Antigen Mismatched Versus Matched Unrelated Donor Hematopoietic Cell Transplantation,. Blood, 2011, 118, 4165-4165.	1.4	0
191	Adverse Immunologic, Cytogenetic, and Molecular Features of AML in Elderly Patients Could Be Overcome by Allogeneic Hematopoietic Cell Transplantation Following Reduced Intensity Conditioning. Blood, 2011, 118, 3065-3065.	1.4	0
192	FLT3-ITD Signaling Induces Oncogenic Mir-155 by NF-κB and STAT5 Pathways In Acute Myeloid Leukemia Thereby Targeting Transcription Factor PU.1,. Blood, 2011, 118, 3469-3469.	1.4	0
193	Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. Haematologica, 2010, 95, 637-643.	3.5	42
194	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 2010, 115, 453-474.	1.4	2,963
195	Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation, 2010, 45, 219-234.	2.4	297
196	Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 405-411.	1.6	285
197	Hematopoietic Stem Cell Transplantation <subtitle>A Global Perspective</subtitle> . JAMA - Journal of the American Medical Association, 2010, 303, 1617.	7.4	556
198	Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia, 2009, 23, 635-640.	7.2	72

DIETGER NIEDERWIESER

#	Article	IF	CITATIONS
199	Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. Bone Marrow Transplantation, 2009, 43, 1-12.	2.4	37
200	Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia. Current Opinion in Oncology, 2009, 21, S17-S22.	2.4	9
201	Mesenchymal Stem Cells Remain Host-Derived Independent of the Source of the Stem-Cell Graft and Conditioning Regimen Used. Transplantation, 2009, 87, 217-221.	1.0	56
202	Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica, 2009, 94, 94-101.	3.5	199
203	Graft-Versus-Leukemia (GVL) Effect After Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) as Treatment for Acute Myeloid Leukemia (AML): a Survey From the Acute Leukemia Working Party of the EBMT Blood, 2009, 114, 3313-3313.	1.4	0
204	Reduction of Relapse Incidence and Improvement of Leukemia Free Survival by Allogeneic Stem Cell Transplantation in Patients with AML and Normal Karyotype Irrespective of the FLT3-ITD Status Blood, 2009, 114, 1612-1612.	1.4	0
205	T-Cell Depletion in Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective EBMT Analysis Blood, 2009, 114, 2307-2307.	1.4	4
206	Patients with Imatinib Resistance Harbour Low Level Mutations of the BCR-ABL Kinase Domain Predominantly in the CD34+ Cells Blood, 2009, 114, 3267-3267.	1.4	0
207	Mobilization of Allogeneic Peripheral Blood Stem Cells in Family Donors with Single-Dose Pegfilgrastim Blood, 2009, 114, 2148-2148.	1.4	0
208	Unrelated Stem Cell Transplantation After Reduced Intensity Conditioning for Patients with Multiple Myeloma Relapsing After Autologous Transplantation A Prospective Multicenter Phase II Study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (FBMT) Blood 2009, 114, 2308-2308	1.4	0
209	Mobilized Peripheral Blood Stem Cells (PBSC) Compared with Bone Marrow (BM) as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced Intensity Conditioning (RIC-alloSCT) in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR): a Retrospective Analysis From the ALWP of EBMT Blood, 2009, 114, 527-527.	1.4	0
210	NME-2 Protein Functions as a Tumour Associated Antigen in HLA-A2+ Cells and Is Over Expressed in CML Via a Bcr/Abl Dependent Post Transcriptional Mechanism Blood, 2009, 114, 3266-3266.	1.4	0
211	Allogeneic Stem Cell Transplantation for Acquired Aplastic Anemia: Better Outcome with Bone Marrow as Compared to Peripheral Blood in HLA-Matched Sibling Donor Transplantation and Improved Outcome Over Time After Matched Unrelated Donor Transplantation. A Retrospective Analysis of Transplants Reported to the German Registry for Stem Cell Transplantation (DRST) Blood,	1.4	0
212	Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stemâ€cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. British Journal of Haematology, 2008, 143, 191-200.	2.5	78
213	Spontaneous Remission of Acute Myeloid Leukemia Relapse after Hematopoietic Cell Transplantation in a High-Risk Patient with 11q23/MLL Abnormality. Acta Haematologica, 2008, 119, 111-114.	1.4	5
214	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. Journal of Clinical Oncology, 2008, 26, 4912-4920.	1.6	257
215	Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology, 2008, 5, 256-267.	4.3	78
216	Hematopoietic Stem Cell Transplantation following Reduced Intensity Conditioning for High Risk Patients with Paroxysmal Nocturnal Hemoglobinuria. Blood, 2008, 112, 4407-4407.	1.4	0

#	Article	IF	CITATIONS
217	Kinetics of BCR-ABL Mutant Clones Determines Resistance in CML on Second Generation TKI Treatment Blood, 2008, 112, 2127-2127.	1.4	0
218	Mito-FLAG with Ara-C as Bolus Vs. Continuous Infusion in Recurrent AML – Results of a Prospective Randomized Intergroup Study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemias (SAL). Blood, 2008, 112, 2972-2972.	1.4	0
219	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 2007, 110, 2744-2748.	1.4	156
220	Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica, 2007, 92, 95-100.	3.5	341
221	Allogeneic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndrome (t-MDS) and Acute Myeloid Leukemia. A Report from the MDS Subcommittee of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Blood, 2007, 110, 252-252.	1.4	3
222	Evidence for a Metabolic Stem Cell Niche Blood, 2007, 110, 4046-4046.	1.4	1
223	Impact of the Donor Recipient Sex Combination in Hematopoietic Stem Cell Transplantation: H-Y as a Model for the Interaction between Major and Minor Histocompatibility Antigens Blood, 2007, 110, 481-481.	1.4	2
224	Factors Influencing Relapse after Allogeneic Hematopoietic Cell Transplantation (HCT) Following Reduced Intensity Conditioning (RIC) in Patients with AML and MDS Blood, 2007, 110, 1654-1654.	1.4	0
225	Outcome of Relapsed Philadelphia Chromosome Positive Chronic Myeloid Leukemia (Ph+ CML) after Allogeneic Hematopoietic Cell Transplantation (HCT) Blood, 2007, 110, 3230-3230.	1.4	0
226	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. Journal of Clinical Oncology, 2006, 24, 444-453.	1.6	243
227	Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Practice and Research in Clinical Haematology, 2006, 19, 825-838.	1.7	30
228	Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisoneâ€"a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical	2.5	175
229	Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2006, 24, 4150-4157.	1.6	104
230	5-Azacitidine Induces Hematologic Responses in a High Proportion of Patients with Acute Myeloid Leukaemia Refractory to or Not Eligible for Intensive Chemotherapy Blood, 2006, 108, 1953-1953.	1.4	1
231	Prognostic Significance of Quantitative t(14;18) PCR Monitoring in Advanced Stage Follicular Lymphoma Patients Blood, 2006, 108, 2757-2757.	1.4	1
232	Treatment with Bendamustine, Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Phase I Clinical Trial Blood, 2006, 108, 3564-3564.	1.4	8
233	Donor CD34+ Cell Chimerism at Day 28 and Chronic Graft-Versus-Host Disease (GvHD) but Not High-Risk Cytogenetics Influence Outcome of Allogeneic Hematopoetic Cell Transplantation (HCT) Following Reduced Intensity Conditioning (RIC) in Patients with AML and MDS Blood, 2006, 108, 547-547.	1.4	1
234	Minor Histocompatibility Antigen HA-1-Specific Immune Reactions after Hematopoietic Cell Transplantation (HCT) Blood, 2006, 108, 5183-5183.	1.4	0

#	Article	IF	CITATIONS
235	Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica, 2006, 91, 513-21.	3.5	184
236	Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood, 2005, 106, 2969-2976.	1.4	163
237	Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. Critical Reviews in Oncology/Hematology, 2005, 56, 275-281.	4.4	14
238	Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia, 2005, 19, 1029-1033.	7.2	149
239	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia, 2005, 19,	7.2	417
240	Evidence for Restricted Glycolytic Metabolism in Primary CD133+ Cells Blood, 2005, 106, 1726-1726.	1.4	5
241	Primary CNS Lymphoma Treated with HD-Methotrexate, HD-Busulfan/Thiotepa, Autologous Stem Cell Transplantation and Response-Adapted Whole-Brain Radiotherapy: Results of the Multicenter OSHO-53 Phase II - Study Blood, 2005, 106, 3342-3342.	1.4	2
242	Treatment of Steroid-Resistant Acute GvHD with OKT3 and High-Dose Steroids Versus High-Dose Steroids Versus High-Dose Steroids Alone Blood, 2005, 106, 141-141.	1.4	4
243	Comparable Distribution of Minimal Residual Diesease between CD34 Positive Hematopoietic Progenitors, CD34 Negative Cells and Total White Cells in Patients with Chronic Myeloid Leukemia (CML) in Molecular Response Blood, 2005, 106, 1985-1985.	1.4	Ο
244	Phlebotomy as an Effective Treatment for Iron Overload after Allogeneic Hematopoietic Cell Transplantation: Iron Depletion Kinetics Are Influenced by the Donor Hemochromatosis (HFE) Genotype Blood, 2005, 106, 3717-3717.	1.4	0
245	Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Conventional Chemotherapy: Final Results of a Phase I Study Blood, 2005, 106, 5154-5154.	1.4	Ο
246	CMV-Seropositive Patients Allografted with a CMV-Seronegative Donor Show Delayed or Missing CMV-Specific T-Cell Immune Response and Are at Higher Risk for CMV-Viremia and CMV-Disease Blood, 2005, 106, 3249-3249.	1.4	0
247	Periodicity of Differentiation and Self-Renewal Suggest Homeostatic Feedback Control of Commitment in a Hematopoietic Progenitor Cell Line Blood, 2005, 106, 4198-4198.	1.4	1
248	Donor Lymphocyte Transfusion (DLT) in the Treatment of Relapsed CML after Allogeneic PBSCT - A Retrospective Analysis of 346 Patients by the EBMT Chronic Leukemia Working Party Blood, 2005, 106, 704-704.	1.4	0
249	Transmission of donor illness by stem cell transplantation: should screening be different in older donors?. Bone Marrow Transplantation, 2004, 34, 657-665.	2.4	48
250	BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia, 2004, 18, 1468-1475.	7.2	25
251	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood, 2004, 103, 790-795.	1.4	124
252	In Vitro Purging in Autologous Stem Cell Transplantation for Chronic Lymphocytic Leukaemia. A Retrospective Analysis on Behalf of the Chronic Leukaemia Working Party of the EBMT Blood, 2004, 104, 148-148.	1.4	2

DIETGER NIEDERWIESER

#	Article	IF	CITATIONS
253	Persistently Increased Creatine Kinase Levels in Patients with Chronic Myeloid Leukemia Treated with Imatinib Correlate with Major Cytogenetic Remission Blood, 2004, 104, 2933-2933.	1.4	10
254	Characteristics of Immunoglobulin Deficiency in Patients with Untreated Multiple Myeloma Stage II and III Blood, 2004, 104, 4861-4861.	1.4	1
255	Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma (MM): Preliminary Results of a Phase I Clinical Trial Blood, 2004, 104, 4901-4901.	1.4	0
256	Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia, 2003, 17, 941-959.	7.2	93
257	Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia, 2003, 17, 841-848.	7.2	180
258	Hematopoietic cell transplantation from related and unrelated donors after minimal conditioning as a curative treatment modality for severe paroxysmal nocturnal hemoglobinuria. Biology of Blood and Marrow Transplantation, 2003, 9, 689-697.	2.0	46
259	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 2003, 101, 1620-1629.	1.4	424
260	Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood, 2003, 102, 4255-4260.	1.4	217
261	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood, 2003, 102, 2021-2030.	1.4	320
262	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 2001, 97, 3390-3400.	1.4	1,306
263	Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. British Journal of Haematology, 2001, 113, 209-216.	2.5	307
264	HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia. British Journal of Haematology, 2001, 114, 36-41.	2.5	17
265	Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens. Bone Marrow Transplantation, 2001, 27, 1125-1132.	2.4	4
266	Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). British Journal of Haematology, 2000, 110, 620-630.	2.5	231
267	EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparison. European Journal of Haematology, 2000, 65, 97-103.	2.2	77
268	Phenotypic and Functional Lymphocyte Recovery After CD34+-Enriched Versus Non-T Cell-Depleted Autologous Peripheral Blood Stem Cell Transplantation. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 727-736.	1.8	25
269	Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet, The, 1998, 352, 1087-1092.	13.7	609
270	Double high-dose chemotherapy with autologous peripheral stem cell rescue in relapsed Wilms' tumor. Bone Marrow Transplantation, 1997, 20, 1111-1113.	2.4	18

#	Article	IF	CITATIONS
271	Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]. Blood, 1995, 86, 2041-2050.	1.4	1,911
272	Prophylactic use of interferon alfa after bone marrow transplantation for patients with chronic myelogenous leukemia at high risk of relapse: a pilot study. The Chronic Leukemia Working Party of the EBMT. Seminars in Hematology, 1993, 30, 40-3.	3.4	4